XML 20 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands
Total
Common Stock and Additional Paid-in Capital [Member]
Parent [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Noncontrolling Interest [Member]
Series A junior participating preferred stock [Member]
Class A Common Stock (Shares) [Member]
Class B Common Stock (Shares) [Member]
Convertible Preferred Stock
Total CME Group Shareholders' Equity, beginning at Dec. 31, 2020   $ 21,189,100,000 $ 26,319,900,000 $ 4,995,900,000 $ 134,900,000          
Noncontrolling Interest, beginning balance at Dec. 31, 2020           $ 31,600,000        
Total Equity at Dec. 31, 2020 $ 26,351,500,000                  
Beginning Balance (in shares) at Dec. 31, 2020               358,110 3 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income attributable to CME Group 2,636,400,000   2,636,400,000 2,636,400,000            
Net income (loss) attributable to non-controlling interests           500,000        
Net income 2,636,900,000                  
Other comprehensive income/(loss) (81,400,000)   (81,400,000)   (81,400,000)          
Dividends, Cash (2,480,400,000)   (2,480,400,000) (2,480,400,000)            
Sale of Stock, Consideration Received on Transaction   965,000,000.0                
Impact of accounting standards update adoption 965,000,000.0   965,000,000.0            
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests   (20,500,000) (20,500,000)              
Exercise of stock options (in shares)               101    
Exercise of stock options 5,500,000 5,500,000 5,500,000              
Vesting of issued restricted Class A common stock, shares               336    
Vesting of issued restricted Class A common stock, value (31,700,000) (31,700,000) (31,700,000)              
Shares issued to Board of Directors (in shares)               14    
Stock Issued to Board of Directors, Value, Issued for Services 2,900,000 2,900,000 2,900,000              
Shares issued under Employee Stock Purchase Plan (in shares)               38    
Shares issued under Employee Stock Purchase Plan 8,400,000 8,400,000 8,400,000              
Stock-based compensation 75,200,000 75,200,000 75,200,000              
Total CME Group Shareholders' Equity, ending at Dec. 31, 2021   22,193,900,000 27,399,300,000 5,151,900,000 53,500,000          
Noncontrolling Interest, ending balance at Dec. 31, 2021           0        
Total Equity at Dec. 31, 2021 27,399,300,000                  
Ending Balance (in shares) at Dec. 31, 2021               358,599 3 4,584
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Changes in non-controlling interest due to measurement period adjustments (52,600,000)         $ (32,100,000)        
Net income attributable to CME Group 2,691,000,000   2,691,000,000 2,691,000,000            
Net income 2,691,000,000                  
Other comprehensive income/(loss) (186,800,000)   (186,800,000)   (186,800,000)          
Dividends, Cash     (3,096,100,000) (3,096,100,000)            
Exercise of stock options (in shares)               1    
Exercise of stock options   100,000 100,000              
Vesting of issued restricted Class A common stock, shares               269    
Vesting of issued restricted Class A common stock, value   (24,800,000) (24,800,000)              
Shares issued to Board of Directors (in shares)               19    
Stock Issued to Board of Directors, Value, Issued for Services   4,000,000.0 4,000,000.0              
Shares issued under Employee Stock Purchase Plan (in shares)               41    
Shares issued under Employee Stock Purchase Plan   7,700,000 7,700,000              
Stock-based compensation   84,300,000 84,300,000              
Total CME Group Shareholders' Equity, ending at Dec. 31, 2022 26,878,700,000 22,265,200,000 26,878,700,000 4,746,800,000 (133,300,000)          
Ending Balance (in shares) at Dec. 31, 2022               358,929 3 4,584
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Preferred Stock, Shares Issued             4,584      
Net income attributable to CME Group 3,226,200,000   3,226,200,000 3,226,200,000            
Net income 3,226,200,000                  
Other comprehensive income/(loss) 77,700,000   77,700,000   77,700,000          
Dividends, Cash     (3,517,800,000) (3,517,800,000)            
Vesting of issued restricted Class A common stock, shares               241    
Vesting of issued restricted Class A common stock, value   (21,400,000) (21,400,000)              
Shares issued to Board of Directors (in shares)               20    
Stock Issued to Board of Directors, Value, Issued for Services   3,600,000 3,600,000              
Shares issued under Employee Stock Purchase Plan (in shares)               41    
Shares issued under Employee Stock Purchase Plan   8,000,000.0 8,000,000.0              
Stock-based compensation   82,900,000 82,900,000              
Total CME Group Shareholders' Equity, ending at Dec. 31, 2023 $ 26,737,900,000 $ 22,338,300,000 $ 26,737,900,000 $ 4,455,200,000 $ (55,600,000)          
Ending Balance (in shares) at Dec. 31, 2023               359,231 3 4,584
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Preferred Stock, Shares Issued 4,600           4,584